Results 151 to 160 of about 4,852 (207)

Design of a Drug-Eluting Subcutaneous Implant of the Antiretroviral Tenofovir Alafenamide Fumarate. [PDF]

Pharm Res, 2020
Simpson SM, Widanapathirana L, Su JT, Sung S, Watrous D, Qiu J, Pearson E, Evanoff A, Karunakaran D, Chacon JE, Kiser PF.   +10 more
europepmc   +1 more source

Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults

, 2017
François Raffi, Chloe Orkin, Amanda Clarke, Laurence Slama, Joel E. Gallant, Eric S. Daar, Keith Henry, Jorge Santana‐Bagur, David Stein, Nicholaos Bellos, Anthony Scarsella, Mingjin Yan, Michael E. Abram, Andrew Cheng, Martin S. Rhee   +14 more
openalex   +1 more source

Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers. [PDF]

Clin Pharmacokinet
Bevers LAH, Kamphuis AEM, van der Wekken-Pas LCW, Leisegang R, Burger DM, Colbers A.   +5 more
europepmc   +1 more source

Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer [PDF]

Pin‐Nan Cheng, Ming‐Lung Yu
openalex   +1 more source

Assessment of risk factors for virological nonsuppression following switch to dolutegravir and lamivudine, or bictegravir, emtricitabine, and tenofovir alafenamide fumarate in a real-world cohort of treatment-experienced adults living with HIV. [PDF]

PLoS One
Lee SY, Lin YC, Chen CP, Cheng SH, Chang SY, Ku SY, Cheng CY.   +6 more
europepmc   +1 more source

Dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate: Real-world assessment of effectiveness and weight Gain in naïve people living with HIV of Asian OrigiN (DRAGON) [PDF]

Chia‐Jui Yang, Linghua Li, Qingxia Zhao, Wen-Hsin Hsih, Mao-Wang Ho, Tsung‐Chia Chen, Mao-Song Tsai, Shu-Yuan Lee, Yi‐Chun Lin, Cheng‐Pin Chen, Shu‐Hsing Cheng, Xue Zhang, Meiyin Zou, Yiwen Wu, Miao‐Hui Huang, Tung-Che Hung, Hsin-Hao Lai, Ping Ma, Chien‐Yu Cheng   +18 more
openalex   +1 more source

Bone turnover change after randomized switch from tenofovir disoproxil to tenofovir alafenamide fumarate in men with HIV. [PDF]

AIDS
Moore AEB, Burns JE, Sally D, Milinkovic A, Krokos G, John J, Rookyard C, Borca A, Pool ERM, Tostevin A, Harman A, Dulnoan DS, Gilson R, Arenas-Pinto A, Cook GJR, Saunders J, Saunders J, Dunn D, Blake GM, Pett SL.   +19 more
europepmc   +1 more source

Clinical Characteristics of Hepatitis B Virus Patients After Switching to Tenofovir Alafenamide Fumarate: A Retrospective Observational Study. [PDF]

Cureus, 2020
Alghamdi AS, Alothmani HS, Mogharbel M, Albiladi H, Babatin M.   +4 more
europepmc   +1 more source

Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer - author's reply. [PDF]

Clin Mol Hepatol
Hong H, Choi J.
europepmc   +1 more source

Changes in Glomerular Filtration Rate After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Fumarate for Human Immunodeficiency Virus Preexposure Prophylaxis. [PDF]

Open Forum Infect Dis
Rivera AS, Pak K, Mefford MT, Hechter RC.   +3 more
europepmc   +1 more source